Sana biotechnology announces preclinical data published in nature biotechnology demonstrating its hypoimmune-engineered cells escape immune detection and survive while remaining fully functional

Hypoimmune-modified allogeneic ipscs evade immune response and rejection without immunosuppression in non-human primate model

SANA Ratings Summary

SANA Quant Ranking